Regenxbio (RGNX) Non-Current Deffered Revenue (2015 - 2025)

Regenxbio's (RGNX) quarterly Non-Current Deffered Revenue came in at $18.9 million in Q4 2025, down 10.59% quarter-over-quarter from $21.2 million in Q3 2025.

Regenxbio (RGNX) Non-Current Deffered Revenue (2015 - 2025) Analysis & Trends

Regenxbio's Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $18.9 million for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $18.9 million in Q4 2025; TTM through Dec 2025 was $18.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $18.9 million, changed N/A from the prior year.
  • Non-Current Deffered Revenue retreated to $18.9 million in Q4 2025 per RGNX's latest filing, from $21.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $26.3 million in Q1 2025 and bottomed at $3.5 million in Q3 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 225.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Regenxbio 528.62 Mn 298.55 Mn 21.22 Mn 18.94 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 18.94 Mn
Sep 30, 2025 21.19 Mn
Jun 30, 2025 23.80 Mn
Mar 31, 2025 26.30 Mn
Sep 30, 2021 3.53 Mn
Jun 30, 2021 3.63 Mn
Mar 31, 2021 3.73 Mn
Dec 31, 2020 3.78 Mn
Sep 30, 2020 3.90 Mn
Jun 30, 2020 4.01 Mn
Mar 31, 2020 3.33 Mn
Dec 31, 2019 3.33 Mn
Sep 30, 2019 3.33 Mn
Jun 30, 2019 3.33 Mn
Mar 31, 2019 3.33 Mn
Dec 31, 2018 3.33 Mn
Sep 30, 2018 1.12 Mn
Jun 30, 2018 1.19 Mn
Mar 31, 2018 1.23 Mn
Dec 31, 2017 1.21 Mn